Press Release: PSMAddition data show Novartis -2-

Novartis

104.06 CHF 0.42%

• Charts
• News
• Analysen

Kaufen Verkaufen

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

Disclosure: Dr. Tagawa is a paid consultant for Novartis.

References

1. Novartis. Data on file.

2. Hussain M, Fizazi K, Shore ND, et al. Metastatic hormone-sensitive

prostate cancer and combination treatment outcomes. JAMA

Oncol. 2024;10(6):807-820.

3. Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate

cancer: advances in treatment and symptom management. Curr Treat Options

Oncol. 2024;25(7):914-931.

4. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change

of androgen receptor pathway inhibitor therapy for taxane-naive patients

with progressive metastatic castration-resistant prostate cancer

(PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024.

doi:10.1016/S0140-6736(24)01653-2.

5. Sartor O, de Bono J, Chi KN, et al. Lutetium-177--PSMA-617 for Metastatic

Castration-Resistant Prostate Cancer. N Engl J Med.

2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322.

6. Pluvicto [prescribing information]. East Hanover, NJ: Novartis

Pharmaceuticals Corporation; 2025.

7. Verry C, Vincendeau S, Massetti M, et al. Pattern of clinical progression

until metastatic castration-resistant prostate cancer: an epidemiological

study from the European Prostate Cancer Registry. Target

Oncol. 2022;17(4):441-451.

8. Wenzel M, Siech C, Hoeh B, et al. Contemporary treatment patterns and

oncological outcomes of metastatic hormone-sensitive prostate cancer and

first- to sixth- line metastatic castration-resistant prostate cancer

patients. Eur Urol Open Sci. 2024;66:46-54.

9. Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world

treatment patterns and overall survival among men with Metastatic

Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare

population. Prostate Cancer Prostatic Dis. 2024;27(2):327-333.

10. Holmstrom S, Naidoo S, Turnbull J, et al. Symptoms and impacts in

metastatic castration-resistant prostate cancer: qualitative findings

from patient and physician interviews. Patient. 2019;12(1):57-67.

11. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on

management in patients with biochemically recurrent prostate cancer. J

Nucl Med. 2017;58(12):1956-61.

12. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific

membrane antigen (PSMA) on biopsies is an independent risk stratifier of

prostate cancer patients at time of initial diagnosis. Front Oncol.

2018;8:623.

13. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane

antigen expression in prostatic intraepithelial neoplasia and

adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256-61.

14. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT

for bone metastasis detection in prostate cancer patients: potential

impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-11.

15. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is

associated with early PSA recurrence in surgically treated prostate

cancer. Prostate. 2011;71(3):281-8.

16. Clinicaltrials.gov. NCT04720157. An International Prospective Open-label,

Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With

SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition).

Accessed October 2025. https://clinicaltrials.gov/study/NCT04720157.

17. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate

Cancer (Pluvicto). Accessed October 2025.

https://www.uchicagomedicine.org/cancer/types-treatments/prostate-cancer/treatment/lutetium-177-psma-therapy-for-prostate-cancer.

18. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision

Cancer Treatment [published correction appears in AJR Am J Roentgenol.

2017 Oct;209(4):949. doi:10.2214/AJR.17.18875]. AJR Am J Roentgenol.

2017;209(2):277-288. doi:10.2214/AJR.17.18264.

19. Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In:

Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical

Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations Central investor

relations line: +41 61 324 7944 E-mail:

investor.relations@novartis.com

(END) Dow Jones Newswires

October 19, 2025 10:30 ET (14:30 GMT)